Compare CleanSpark Inc (CLSK) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CleanSpark Inc vs Crispr Therapeutics AG — how do they compare? CleanSpark Inc trades at $12.16 (market cap $2.96B), while Crispr Therapeutics AG trades at $53.81 (market cap $5.23B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap. Which is the better fit depends on your goals.
| CLSK | CRSP | |
|---|---|---|
Market Cap | $2.96B | $5.23B |
Sector | Technology | Health |
52-Week High | $23.20 | $76.78 |
52-Week Low | $8.18 | $44.34 |
Enterprise Value | $3.95B | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CleanSpark (CLSK) trades at $12.08, up 4.23% today but facing bearish technical signals with recent earnings misses. The company reported a Q3 2026 loss of $0.89 per share versus expectations of -$0.47, continuing a trend of negative profitability despite securing a significant $6.6 billion AI data center lease. Analyst sentiment remains strongly bullish with 11 buy ratings and a $24.13 consensus price target, representing 100% upside potential from current levels.
The stock presents a high-risk, high-reward opportunity with strong institutional support but significant execution challenges. While the AI infrastructure pivot offers long-term growth potential, near-term profitability concerns and negative cash flow create substantial volatility. Investors must weigh the disconnect between bullish analyst coverage and persistent earnings underperformance against the company's strategic repositioning in digital infrastructure.
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CleanSpark Inc
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
